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The mechanisms by which SGLT-2 inhibitors lower albuminuria are incompletely understood.
We assessed in a post-hoc analysis of a cross-over trial the effects of the SGLT2 inhibitor dapa-
gliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM-
1, NGAL and LFABP) and inflammatory markers (urinary MCP-1 and IL-6) to provide more
insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI,
30.3%-54.8%) and eGFR by 5.1 (2.0-8.1) mL/min/1.73m2 compared to placebo. Dapagliflozin
did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin
decreased urinary KIM-1 excretion by 22.6% (0.3%-39.8%; P = .05) and IL-6 excretion by 23.5%
(1.4%-40.6%; P = .04) compared to placebo, whereas no changes in NGAL, LFABP and MCP-1
were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes
in eGFR (r = 0.36; P = .05) and KIM-1 (r = 0.39; P = .05). In conclusion, the albuminuria-
lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomeru-
lar pressure or reduced tubular cell injury.
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1 | INTRODUCTION
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors lower glycated hae-
moglobin (HbA1c), decrease blood pressure, body weight and albuminuria,
and, in the long-term, SGLT-2 inhibitors appear to slow progression of kid-
ney function decline.1–3 The mechanisms responsible for the albuminuria-
lowering effect are not yet completely understood. A reduction in glomer-
ular hyperfiltration as a result of restoration of tubuloglomerular feedback
may be 1 of the potential mechanisms.4,5 SGLT-2 inhibitors could also
hypothetically lower albuminuria by restoring the charge and/or size
selectivity of the glomerular basement membrane. Alternatively, improve-
ment in tubular reabsorption of filtered albumin can potentially decrease
albuminuria.6 SGLT-2 inhibition reduces the reabsorption of filtered
sodium and glucose in the proximal tubule, and thereby reduces the
oxygen-consuming transport workload. Less oxygen stress may help to
improve tubular cell integrity and, potentially, tubular albumin reabsorp-
tion.7,8 As hyperglycaemia and albuminuria have proinflammatory
influences on renal tubules, reductions in these parameters could, hypo-
thetically, reduce the generation of proinflammatory cytokines.9
Various biomarkers that are associated with glomerular and tubu-
lar structure and function are presently available. The aim of the cur-
rent study was to characterize the effect of the SGLT-2 inhibitor
dapagliflozin on glomerular and tubular injury and inflammatory
markers. Secondly, we assessed whether changes in albuminuria or
eGFR during dapagliflozin therapy correlated with kidney injury
markers to provide insight into the mechanisms responsible for the
lowering of albuminuria with dapagliflozin.
2 | MATERIALS AND METHODS
2.1 | Study design and patients
This was a post-hoc analysis of a prospective, randomized, double-
blind, placebo-controlled cross-over clinical trial. The study design,
Received: 21 January 2018 Revised: 9 March 2018 Accepted: 20 March 2018
DOI: 10.1111/dom.13301
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original
work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Diabetes Obes Metab. 2018;1–6. wileyonlinelibrary.com/journal/dom 1
patient population and primary results have been described previ-
ously.10 In short, 33 patients with type 2 diabetes, aged between
18 and 75 years, with a first morning void albumin:creatinine ratio
(UACR) ≥ 100 mg/g and < 3500 mg/g (11.3-395.5 mg/mmol) and an
eGFR ≥45 mL/min/1.73m2 were enrolled. Participants were required
to have been using a maximum tolerated stable dose of an angiotensin
converting enzyme inhibitor or angiotensin receptor blocker for more
than 4 weeks. Patients were randomly assigned to 2 consecutive
treatment periods of 6 weeks, during which they received dapagliflo-
zin 10 mg per day or placebo, with wash-out periods of 6 weeks in
between. The primary outcome was change in 24-hour urinary albu-
min excretion rate (24 hour UAE). The study was registered with the
Netherlands Trial Register (NTR 4439) and complied with the Declara-
tion of Helsinki and Good Clinical Practice Guidelines.
2.2 | Measurements
Blood and urine samples were obtained at baseline, in the beginning
and at the end of the 2 treatment periods, as well as at the end of the
wash-out period. These urine and plasma samples were stored at
−80 C for no more than 24 months (range, 6-24 months). Blood and
urine samples from 31 patients were available for this study.
Urinary IgG and IgG4 were measured as markers of glomerular
damage. Urinary kidney injury molecule-1 (KIM-1), neutrophil
gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-
binding protein (LFABP) were measured as markers of tubular damage.
Urinary monocyte chemoattractant protein-1 (MCP-1) and urinary
interleukin-6 (IL-6) were measured as markers of inflammation.11 To
assess the effect of dapagliflozin on size-selectivity and charge-
selectivity of the glomerular basement membrane, plasma IgG and
IgG4 were also determined. The ratio of IgG to albumin clearance was
calculated as an index of glomerular size selectivity.12 Glomerular
charge selectivity was calculated by the ratio of the clearance of the
neutrally charged IgG to the clearance of the negatively charged
IgG4.12 For quantification of IgG4, KIM-1, NGAL, LFABP, MCP-1 and
IL-6, direct sandwich-ELISAs were used according to the manufac-
turer's specifications (R&D systems, Minneapolis, Minnesota). IgG was
quantified with nephelometry.
2.3 | Statistical analysis
The effect of dapagliflozin compared to placebo on the kidney injury
markers was determined with a mixed effects repeated measures
analysis. The model included sequence, period, treatment and subject
as factors and baseline biomarker of interest as a covariate. All bio-
markers were log transformed before entering data in the repeated
measures model. The between-group geometric mean change in
24-hour excretion of the biomarker of interest was derived by 100*
(exp[least square mean change]-1), and the same transformation was
applied to the 95% confidence limits. Pearson's correlation coefficient
was used to calculate correlations between eGFR, 24 hour UAE and
kidney injury markers. All variables were log transformed before calcu-
lation of the Pearson's correlation coefficient. SAS software version
82 (SAS Institute, Inc., Cary, North Carolina) was used. All statistical
tests were 2-sided, with a statistical significance level of P value < .05.
3 | RESULTS
Baseline characteristics of the 31 patients with available urine and
plasma samples are reported online in Table S1. Dapagliflozin
decreased 24 hour UAE by 42.5% (95% CI, 29.9%-52.9%; P < .01)
and eGFR by 5.2 mL/min/1.73m2 (2.5-7.8 mL/min/1.73m2; P < .01)
(Figure 1A,B). The decrease in eGFR occurred within the first weeks
of dapagliflozin therapy. Six weeks after dapagliflozin discontinuation
the mean eGFR was 71 (SD, 19) ml/min/1.73m2, indicating that the
decline in eGFR was reversible after treatment discontinuation.
3.1 | Effect of dapagliflozin on glomerular, tubular
and inflammatory markers
Dapagliflozin significantly reduced urinary glomerular damage markers
compared to placebo. Compared to placebo, dapagliflozin decreased
fractional clearance of IgG and IgG4 by 28.4% (95% CI, 7.2%-44.8%;
P = .01) and 34.6% (3.0%-55.9%; P = .04), respectively. However, the
IgG-to-IgG4 clearance ratio (marker of glomerular charge selectivity)
and the IgG-to-albumin clearance ratio (marker of glomerular size
selectivity) did not change significantly during dapagliflozin treatment
compared to placebo (Table 1, Figure 1C,D).
At the tubular level, dapagliflozin, compared to placebo, reduced
urinary KIM-1 excretion by 22.6% (0.3%-39.8%; P = .05) (Table 1 and
Figure 1E), but did not change urinary excretion of NGAL (−13.4%
[−35.6%-16.6%]; P = 0.33) (Table 1 and Figure 1F) or LFABP (0.9%
[−13.2%-17.2%]; P = .91) (Table 1 and Figure 1G).
Changes in urinary excretion of inflammatory biomarkers with
placebo and during dapagliflozin therapy are shown in Table 1 and
Figure 1H,I. Dapagliflozin, compared to placebo, reduced urinary IL-6
excretion by 23.5% (1.4%-40.6%; P = .04) and urinary MCP-1 excre-
tion by 14.1% (−32.2%-8.9%; P = .20).
3.2 | Correlations between 24 hour UAE, eGFR and
kidney injury markers
At baseline, 24 hour UAE correlated with urinary NGAL, LFABP and
IL-6 excretions (Table S2). During dapagliflozin treatment there was a
significant correlation between 24 hour UAE change and eGFR
change (r = 0.36; P = .05) (Figure S1A). Changes in 24 hour UAE did
not correlate with changes in IgG to IgG4 clearance ratio (r = −0.01;
P = .97) and IgG to albumin clearance ratio (r = −0.36; P = .06).
Changes in KIM-1 excretion significantly correlated with changes in
24 hour UAE (r = 0.39; P = .05) (Figure S1D–F). There were no corre-
lations between changes in the other tubular biomarkers and changes
in 24 hour UAE. Both reductions in IL-6 and MCP-1 excretions corre-
lated with reductions in 24 hour UAE (r = 0.59; P < .01 and r = 0.44;
P = .02, respectively) (Figure S1G,H). Figure S2 shows that there were
no correlations between eGFR changes and changes in any of the kid-
ney injury markers during dapagliflozin therapy. Finally, after 6 weeks
of dapagliflozin treatment, the residual 24 hour UAE level correlated
with achieved urinary excretion of KIM-1, LFABP, NGAL, IL-6 and
MCP-1 (Table S2).
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4 | DISCUSSION
This study assessed the effects of dapagliflozin on glomerular, tubular
and inflammatory biomarkers in patients with type 2 diabetes and
albuminuria. Dapagliflozin decreased urinary KIM-1 and IL-6 excre-
tion, suggesting that dapagliflozin may beneficially affect renal inflam-
mation and reduces ischemic proximal tubular cell injury.
Reductions in urinary albumin excretion can be a consequence of
changes in charge and/or size selectivity of the glomerular filtration
barrier, decreased intraglomerular pressure or improved tubular reab-
sorptive capacity. The lack of effect on IgG-to-IgG4 clearance ratio
and IgG-to-albumin clearance ratio suggests that changes in albumin-
uria in response to dapagliflozin treatment are not a result of effects
on charge and size selectivity of the glomerular filtration barrier.
Therefore, the observed reduction in albuminuria could still be
explained by two other mechanisms: reduced intraglomerular pressure
and improved tubular reabsorption processes.
The reduction in intraglomerular pressure, manifested by the
reversible reduction in eGFR, may better explain the reduction in albu-
minuria as indicated by the positive correlation between eGFR and
albuminuria changes. However, it is unlikely that the reduction in
intraglomerular pressure completely explains albuminuria lowering
with dapagliflozin as the time-course of effects on eGFR and albumin-
uria are different; eGFR changes occur rapidly, whereas effects on
albuminuria probably take longer to be fully manifested. Nevertheless,
acute hemodynamic effects may form the basis of gradual structural
improvements in the glomerular filtration barrier. The albuminuria
reduction observed in the Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUT-
COME) was only partially reversed after treatment discontinuation,
suggesting that SGLT-2 inhibitors induce structural improvements in
the kidney over time.13
Dapagliflozin appeared to decrease urinary KIM-1 excretion, but
there was no effect on urinary NGAL and LFAPB excretion, compared
to placebo. KIM-1 is a specific marker for hypoxic injury to proximal
tubular cells, which would suggest that dapagliflozin reduces proximal
tubular cell injury.14 The reabsorption of electrolyte and organic sol-
utes in the proximal tubule requires much energy.7 The proximal
tubule therefore accounts for the largest amount of oxygen consump-
tion in the kidney. SGLT-2 expression is increased in patients with dia-
betes.5 As a result, more glucose and sodium are reabsorbed, which
increases the oxygen demand of tubular cells. This, in turn, renders
the proximal tubule particularly susceptible to hypoxia in the setting
of type 2 diabetes.7,8 Hypoxia appears to be one of the major drivers
of kidney disease progression, especially in the diabetic kidney.8,15
SGLT-2 inhibition reduces sodium and glucose reabsorption in the
proximal tubule, thereby reducing the workload for proximal tubular
cells. Reduced workload may mitigate hypoxia-induced proximal tubu-
lar damage, which could lead to improved tubular cell structural integ-
rity and, possibly, function.7,8 This notion is supported by a previous
animal study showing that SGLT inhibition with phlorizin in diabetic
rats improved renal cortical oxygen tension.16
We also observed a reduction in the inflammatory marker IL-6
during dapagliflozin treatment. IL-6 is an inflammatory cytokine and
has been implicated in the progression of diabetic kidney disease.17
The presence of cytokines in the urine is thought to reflect local renal
production of these cytokines.18,19 The decrease of IL-6 excretion
observed in our study is in line with previous animal and in vitro stud-
ies.20,21 Previous studies showed that increased albumin leakage into
the tubular compartment triggers an inflammatory response leading to
MCP-1 and IL-6 release.22 The reduction in albumin leakage or tubular
reabsorption may alleviate intra-renal inflammation and release of IL-6
and MCP-1. It is also possible that increasing urinary glucose excretion
reduces intra-renal glucotoxicity and inflammation.9 Unfortunately,
urinary glucose excretion was not measured in our study.
To the best of our knowledge, our study is the first to investigate
the effect of SGLT-2 inhibition on tubular injury markers. Our data
demonstrate that dapagliflozin does not increase tubular injury
markers. In addition, the absence of correlation between changes in
eGFR and changes in kidney injury markers indicates that 6-weeks
TABLE 1 Mean percent changes from baseline in kidney injury markers
Injury markers Baselinea
Mean % change from baseline,
placebo (95% CI)b P value
Mean % change from baseline,
dapagliflozin (95% CI)b P-value
Glomerular
IgG 2269 [875-4600] 4.3 (−12.4, 24.2) .64 −25.3 (−38.1, −9.9) 0.01
IgG4 4 [1–8] 3.6 (−21.0, 36.0) .80 −32.2 (−49.1, −9.7) 0.01
IgG/IgG4 920 [396-1271] −0.9 (−24.0, 29.2) .95 16.7(−11.9, 54.5) 0.29
IgG/Albumin 0.2 [0.2-0.3] 10.9 (1.2, 21.6) .04 18.2 (7.0, 30.4) <0.01
Tubular
KIM-1 1218 [597-2705] −0.9 (−20.4, 23.4) .94 −23.3 (−39.8, −2.2) 0.04
NGAL 23 [13-65] 9.3 (−9.7, 32.3) .37 −5.3 (−22.5, 15.7) 0.60
LFABP 11 [8-17] 21.2 (6.0, 38.5) .01 22.2 (6.4, 40.4) 0.01
Inflammatory
IL-6 3 [2-5] −0.7 (−18.1, 20.5) .95 −24.0 (−37.9, −7.0) 0.01
MCP-1 268 [213-413] 5.6 (−11.1, 25.5) .54 −9.3 (−24.3, 8.7) 0.30
a Baseline data are given as median pg/24 h [25th to 75th percentile] for KIM-1, LFABP, IL-6 and MCP-1, and median ng/24 h for NGAL.
b All biomarkers were log transformed. Mean change in 24-hour excretion of the individual biomarker was derived by 100*(exp[least square mean
change]-1). The same transformation was applied to the 95% confidence limits.
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FIGURE 1 Change in eGFR (ml/min/1.73m2) A; percent change in 24 h UAE B; in IgG/IgG4 C; in IgG/Albumin D; in KIM-1 E; in NGAL F; in
LFABP G; in IL-6 H; and in MCP-1 I during placebo and dapagliflozin treatment. Boxes show mean change within the 25th and 75th percentile.
Mean differences and 95% confidence intervals of eGFR, 24 h UAE and kidney injury markers, compared to placebo, are shown under each sub-
figure. One subject with an IgG/IgG4 change of 4860% is not shown in this figure C, and one subject with an LFABP change of 857% is not
shown in this figure G
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dapagliflozin therapy is not associated with tubular injury, although
large studies, such as CREDENCE and DAPA-CKD, are required to
confirm this finding.
This study has limitations. It was performed as a post-hoc analy-
sis of a short-term study. As such, we were unable to investigate
the long-term effects of SGLT-2 inhibition on glomerular, tubular
and inflammatory biomarkers. It is not clear whether the results
would apply to the sustained effects of dapagliflozin. In addition,
because of the relatively small sample size, the power may have
been too low to detect significant changes in, for example, the
proxies for glomerular charge and size selectivity. These results
should, thus, be regarded as hypothesis generating rather than
hypothesis testing.
In conclusion, dapagliflozin therapy for 6 weeks decreases urinary
excretion of proximal tubular marker KIM-1 and inflammatory marker
IL-6. The observed reduction in albuminuria correlated positively with
the decrease in eGFR, and also with the reduction in KIM-1 excretion.
These findings support the hypothesis that the albuminuria-lowering
effect of dapagliflozin could be the result of a reduction in glomerular
pressure and improved proximal tubular cell integrity.
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